Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 1
2007 1
2008 1
2009 1
2010 1
2011 2
2012 1
2013 4
2014 3
2015 1
2016 1
2017 2
2018 5
2019 3
2020 6
2021 5
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Results by year
Filters applied: . Clear all
Page 1
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms.
Cersosimo F, Barbarino M, Lonardi S, Vermi W, Giordano A, Bellan C, Giurisato E. Cersosimo F, et al. Among authors: barbarino m. Cancers (Basel). 2021 Nov 12;13(22):5664. doi: 10.3390/cancers13225664. Cancers (Basel). 2021. PMID: 34830817 Free PMC article. Review.
Tumour Treating Fields for mesothelioma.
Barbarino M, Bottaro M, Luzzi L, Giordano A, Mutti L. Barbarino M, et al. Lancet Oncol. 2020 Jan;21(1):e8. doi: 10.1016/S1470-2045(19)30829-0. Lancet Oncol. 2020. PMID: 31908312 No abstract available.
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma.
Dell'Anno I, Melani A, Martin SA, Barbarino M, Silvestri R, Cipollini M, Giordano A, Mutti L, Nicolini A, Luzzi L, Aiello R, Gemignani F, Landi S. Dell'Anno I, et al. Among authors: barbarino m. Cancers (Basel). 2022 May 20;14(10):2527. doi: 10.3390/cancers14102527. Cancers (Basel). 2022. PMID: 35626133 Free PMC article.
EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma.
Dell'Anno I, Barbarino M, Barone E, Giordano A, Luzzi L, Bottaro M, Migliore L, Agostini S, Melani A, Melaiu O, Catalano C, Cipollini M, Silvestri R, Corrado A, Gemignani F, Landi S. Dell'Anno I, et al. Among authors: barbarino m. Int J Mol Sci. 2020 Jul 9;21(14):4856. doi: 10.3390/ijms21144856. Int J Mol Sci. 2020. PMID: 32659970 Free PMC article.
Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.
Giannini G, Battistuzzi G, Vesci L, Milazzo FM, De Paolis F, Barbarino M, Guglielmi MB, Carollo V, Gallo G, Artali R, Dallavalle S. Giannini G, et al. Among authors: barbarino m. Bioorg Med Chem Lett. 2014 Jan 15;24(2):462-6. doi: 10.1016/j.bmcl.2013.12.048. Epub 2013 Dec 18. Bioorg Med Chem Lett. 2014. PMID: 24388690 Free article.
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, Landi S. Dell'Anno I, et al. Among authors: barbarino m. Invest New Drugs. 2021 Jun;39(3):644-657. doi: 10.1007/s10637-020-01040-y. Epub 2020 Dec 9. Invest New Drugs. 2021. PMID: 33300108 Free PMC article.
Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
Bargiotti A, Musso L, Dallavalle S, Merlini L, Gallo G, Ciacci A, Giannini G, Cabri W, Penco S, Vesci L, Castorina M, Milazzo FM, Cervoni ML, Barbarino M, Pisano C, Giommarelli C, Zuco V, De Cesare M, Zunino F. Bargiotti A, et al. Among authors: barbarino m. Eur J Med Chem. 2012 Jul;53:64-75. doi: 10.1016/j.ejmech.2012.03.036. Epub 2012 Mar 28. Eur J Med Chem. 2012. PMID: 22538015
39 results